Research, development and production of PARS-LUTOTATE theranostic radiopharmaceutical kit in form of a single vial, is used for the first time in the world for the treatment of neuroendocrine tumors.
After being labeled with Lu-177 radioisotope, this radiopharmaceutical binds to neuroendocrine tumor cells selectively and in a totally intelligent way so that it can destroy them completely. Also, it makes diagnostic imaging and follow-up of the treatment possible. Neuroendocrine tumors are sort of rather rare cancers that arise from special cells which have traits like the endocrine glands (hormonal) and nervous systems, and they may occur anywhere in the body. Most neuroendocrine tumors occur in the lungs, appendix, small intestine, rectum, and pancreas.